1.History of any other COVID-19 investigational/or licensed vaccination. <br/ >2.History of cold, sneezing, nasal obstruction in the past 1 day. <br/ >3.For women of childbearing potential, a positive urine pregnancy test (within 24 hours of administering each dose of vaccine). <br/ >4.Temperature >38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within three days before each dose of vaccine. <br/ >5.Medical problems because of alcohol or illicit drug use during the past 12 months. <br/ >6.Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before enrolment or expects to receive an investigational agent during the study period. <br/ >7.Receipt of any licensed vaccine within four weeks before enrolment in this study. <br/ >8.Known sensitivity to any ingredient of the study vaccines, or a more severe allergic reaction and history of allergies in the past. <br/ >9.Receipt of immunoglobulin or other blood products within the three months before vaccination in this study. <br/ >10.Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months. <br/ >11.Long-term use ( > 2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose inhaled steroids ( >800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding six months (nasal and topical steroids are allowed). <br/ >12.Any history of anaphylaxis concerning vaccination. <br/ >13.History of any cancer. <br/ >14.History of severe psychiatric severe conditions likely to affect participation in the study. <br/ >15.A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or prior history of significant bleeding or bruising following IM injections or venipuncture. <br/ >16.Any other serious chronic illness requiring immediate hospital specialist supervision. <br/ >17.Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol. <br/ >Re-Vaccination Exclusion Criteria <br/ >18.Pregnancy. <br/ >19.Anaphylactic reaction following administration of the vaccine. <br/ >20.Virologically confirmed cases of SARS-CoV-2 infection. <br/ >

1.History of any other COVID-19 investigational/or licensed vaccination. <br/ >2.History of cold, sneezing, nasal obstruction in the past 1 day. <br/ >3.For women of childbearing potential, a positive urine pregnancy test (within 24 hours of administering each dose of vaccine). <br/ >4.Temperature >38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within three days before each dose of vaccine. <br/ >5.Medical problems because of alcohol or illicit drug use during the past 12 months. <br/ >6.Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before enrolment or expects to receive an investigational agent during the study period. <br/ >7.Receipt of any licensed vaccine within four weeks before enrolment in this study. <br/ >8.Known sensitivity to any ingredient of the study vaccines, or a more severe allergic reaction and history of allergies in the past. <br/ >9.Receipt of immunoglobulin or other blood products within the three months before vaccination in this study. <br/ >10.Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months. <br/ >11.Long-term use ( > 2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose inhaled steroids ( >800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding six months (nasal and topical steroids are allowed). <br/ >12.Any history of anaphylaxis concerning vaccination. <br/ >13.History of any cancer. <br/ >14.History of severe psychiatric severe conditions likely to affect participation in the study. <br/ >15.A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or prior history of significant bleeding or bruising following IM injections or venipuncture. <br/ >16.Any other serious chronic illness requiring immediate hospital specialist supervision. <br/ >17.Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol. <br/ >Re-Vaccination Exclusion Criteria <br/ >18.Pregnancy. <br/ >19.Anaphylactic reaction following administration of the vaccine. <br/ >20.Virologically confirmed cases of SARS-CoV-2 infection. <br/ >

N/A

N/A

1.History of any other COVID-19 investigational/or licensed vaccination. <br/ >2.History of cold, sneezing, nasal obstruction in the past 1 day. <br/ >3.For women of childbearing potential, a positive urine pregnancy test (within 24 hours of administering each dose of vaccine). <br/ >4.Temperature >38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within three days before each dose of vaccine. <br/ >5.Medical problems because of alcohol or illicit drug use during the past 12 months. <br/ >6.Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before enrolment or expects to receive an investigational agent during the study period. <br/ >7.Receipt of any licensed vaccine within four weeks before enrolment in this study. <br/ >8.Known sensitivity to any ingredient of the study vaccines, or a more severe allergic reaction and history of allergies in the past. <br/ >9.Receipt of immunoglobulin or other blood products within the three months before vaccination in this study. <br/ >10.Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months. <br/ >11.Long-term use ( > 2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose inhaled steroids ( >800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding six months (nasal and topical steroids are allowed). <br/ >12.Any history of anaphylaxis concerning vaccination. <br/ >13.History of any cancer. <br/ >14.History of severe psychiatric severe conditions likely to affect participation in the study. <br/ >15.A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or prior history of significant bleeding or bruising following IM injections or venipuncture. <br/ >16.Any other serious chronic illness requiring immediate hospital specialist supervision. <br/ >17.Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol. <br/ >Re-Vaccination Exclusion Criteria <br/ >18.Pregnancy. <br/ >19.Anaphylactic reaction following administration of the vaccine. <br/ >20.Virologically confirmed cases of SARS-CoV-2 infection. <br/ >

1.History of any other COVID-19 investigational/or licensed vaccination. <br/ >2.History of cold, sneezing, nasal obstruction in the past 1 day. <br/ >3.For women of childbearing potential, a positive urine pregnancy test (within 24 hours of administering each dose of vaccine). <br/ >4.Temperature >38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within three days before each dose of vaccine. <br/ >5.Medical problems because of alcohol or illicit drug use during the past 12 months. <br/ >6.Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before enrolment or expects to receive an investigational agent during the study period. <br/ >7.Receipt of any licensed vaccine within four weeks before enrolment in this study. <br/ >8.Known sensitivity to any ingredient of the study vaccines, or a more severe allergic reaction and history of allergies in the past. <br/ >9.Receipt of immunoglobulin or other blood products within the three months before vaccination in this study. <br/ >10.Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months. <br/ >11.Long-term use ( > 2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose inhaled steroids ( >800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding six months (nasal and topical steroids are allowed). <br/ >12.Any history of anaphylaxis concerning vaccination. <br/ >13.History of any cancer. <br/ >14.History of severe psychiatric severe conditions likely to affect participation in the study. <br/ >15.A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or prior history of significant bleeding or bruising following IM injections or venipuncture. <br/ >16.Any other serious chronic illness requiring immediate hospital specialist supervision. <br/ >17.Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol. <br/ >Re-Vaccination Exclusion Criteria <br/ >18.Pregnancy. <br/ >19.Anaphylactic reaction following administration of the vaccine. <br/ >20.Virologically confirmed cases of SARS-CoV-2 infection. <br/ >